Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity

Molecular Therapy

Volumn 13, Issue 2, 2006, Pages 347-356

  Barton, Kenneth N ^a   Paielli, Dell ^a   Zhang, Yingshu ^a   Koul, Sweaty ^a   Brown, Stephen L ^a   Lu, Mei ^a   Seely, John ^b   Kim, Jae Ho ^a   Freytag, Svend O ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

Author keywords

Gene therapy; Oncolytic adenovirus; Radiation therapy

Indexed keywords

ADENOVIRUS DEATH PROTEIN; CYTOSINE DEAMINASE; FLUOROURACIL; HYBRID PROTEIN; ONCOLYTIC VIRUS; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOTECHNOLOGY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG SAFETY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SUICIDE GENE THERAPY; THROMBOCYTOPENIA; TUMOR CELL; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRUS E3 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; DOGS; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; CANIS FAMILIARIS; HUMAN ADENOVIRUS TYPE 5; SIMPLEXVIRUS;

EID: 30344477005     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2005.10.005     Document Type: Article

References (33)

1. I. Ganly et al. A phase I study of ONYX-015, an E1B attenuated adenovirus, administered intratumorally to subjects with recurrent head and neck cancer Clin. Cancer Res. 6 2000 798-806
2. J. Nemunaitis et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in subjects with refractory head and neck cancer J. Clin. Oncol. 19 2001 289-298
3. J. Nemunaitis et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in subjects with advanced head and neck cancer: A phase II trial Cancer Res. 60 2000 6359-6366
4. F. Khuri et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in subjects with recurrent head and neck cancer Nat. Med. 6 2000 879-885
5. J. Hecht et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma Clin. Cancer Res. 9 2003 555-561
6. S. Mulvihill et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial Gene Ther. 8 2001 308-315
7. T. Reid et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in subjects with colorectal carcinoma metastatic to the liver: A phase I trial Gene Ther. 8 2001 1618-1626
8. P. Vasey et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in subjects with recurrent/refractory epithelial ovarian cancer J. Clin. Oncol. 20 2002 1562-1569
9. E.A. Chiocca et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting Mol. Ther. 10 2004 958-966
10. T. DeWeese et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy Cancer Res. 61 2001 7464-7472
11. S.O. Freytag K.R. Rogulski D.L. Paielli J.D. Gilbert and J.H. Kim A novel three-pronged approach to selectively kill cancer cells: concomitant viral, double suicide gene, and radiotherapy Hum. Gene Ther. 9 1998 1323-1333
12. K.R. Rogulski M. Wing D.L. Paielli J.D. Gilbert J.H. Kim and S.O. Freytag Double suicide gene therapy augments the therapeutic efficacy of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization Hum. Gene Ther. 11 2000 67-76
13. S.O. Freytag et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model Int. J. Radiat. Oncol. Biol. Phys. 54 2002 873-886
14. J.H. Kim S.H. Kim S.L. Brown and S.O. Freytag Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene Cancer Res. 54 1994 6053-6056
15. J.H. Kim S.H. Kim A. Kolozsvary S.L. Brown O.B. Kim and S.O. Freytag Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents Int. J. Radiat. Oncol. Biol. Phys. 33 1995 861-868
16. M. Khil J.H. Kim C.A. Mullen S.H. Kim and S.O. Freytag Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene Clin. Cancer Res. 2 1996 53-57
17. K.R. Rogulski J.H. Kim S.H. Kim and S.O. Freytag Glioma cells transduced with an E. coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity Hum. Gene Ther. 8 1997 73-85
18. K.R. Rogulski K. Zhang A. Kolozsvary J.H. Kim and S.O. Freytag Pronounced anti-tumor effects and tumor radiosensitization of double suicide gene therapy Clin. Cancer Res. 3 1997 2081-2088
19. J.H. Kim A. Kolozsvary K.R. Rogulski M. Khil and S.O. Freytag Double suicide fusion gene: A selective radiosensitization of 9L glioma in rat brain Can. J. Sci. Am. 4 1998 364-369
20. Y. Xie J.D. Gilbert J.H. Kim and S.O. Freytag Efficacy of adenovirus-mediated CD/5-FC and HSV-1 TK/GCV suicide gene therapies concomitant with p53 gene therapy Clin. Cancer Res. 5 1999 4224-4232
21. S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer Cancer Res. 62 2002 4968-4976
22. S.O. Freytag et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer Cancer Res. 63 2003 7497-7506
23. E. Kievit et al. Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts Cancer Res. 59 1999 1417-1421
24. D. Hamstra D. Rice S. Fahmy B. Ross and A. Rehemtulla Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase Hum. Gene Ther. 10 1999 1993-2003
25. M. Black T. Newcomb H. Wilson and L. Loeb Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy Proc. Natl. Acad. Sci. USA 93 1996 3525-3529
26. M. Black M. Kokoris and P. Sabo Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing Cancer Res. 61 2001 3022-3026
27. A. Tollefson A. Scaria T. Hermiston J. Ryerse L. Wold and W.S. Wold The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells J. Virol. 70 1996 2296-2306
28. A. Tollefson J. Ryerse A. Scaria Hermiston and W.S. Wold The E3-11.6 kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants Virology 220 1996 152-162
29. K. Doronin K. Toth M. Kuppuswamy P. Ward A. Tollefson and W.S. Wold Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein J. Virol. 74 2000 6147-6155
30. K. Doronin et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy J. Virol. 75 2001 3314-3324
31. K. Toth et al. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein Cancer Gene Ther. 10 2003 193-200
32. K. Barton et al. GENIS: Gene expression of sodium iodide symporter for non-invasive imaging of gene therapy vectors and quantification of gene expression in vivo Mol. Ther. 8 2003 508-518
33. K. Barton et al. A quantitative method for measuring gene expression magnitude and volume delivered by gene therapy vectors Mol. Ther. 9 2004 625-631